PHASE 1/2 TRIAL OF ANTI‐PD‐LIGAND 1 (DURVALUMAB) +/‐ LENALIDOMIDE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: PRELIMINARY RESULTS OF PHASE 1 AND CORRELATIVE STUDIES. (12th June 2019) - Querfeld, C.; Zain, J.; Jovanovic‐Talisman, T.; Wakefield, D.L.; Kil, S.; Estephan, R.; Young, P.; Sanchez, J.; Martinez, X.; Stiller, T.; Palmer, J.; Rosen, S.T.